

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

#7

Substitute for Form 1449/A/PTO

SEP 1 8 2000

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

## Complete if Known

Application No.	09/766,778
Filing Date	01/22/2001
First Named Inventor	Papathanassiu et al.
Group Art Unit	1631
Examiner Name	Borin, Michael L.
Attorney Docket Number	05213-0294 (43170-252538)

Sheet 1 of 3

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number <sup>2</sup>	Kind Code <sup>3</sup> (if known)			
mm	1	5,223,409		Ladner et al.	06/29/1993	
	2	5,385,885		Gasic et al.	01/31/1995	
	3	5,589,359		Innis et al.	12/31/1996	
	4	5,770,563		Roberts et al.	06/23/1998	
	5	5,795,865		Markland et al.	08/18/1998	
	6	5,981,471		Papathanassiu et al.	11/09/1999	
mm	7	6,010,880		Markland et al.	01/04/2000	

RECEIVED

SEP 1 8 2000

TECH CENTER 1600 2900

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST-3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible.

<sup>1</sup> Applicant is to place in the blank space of English language patent document, the following:

RECEIVED

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	09/766,778
				Filing Date	01/22/2001
				First Named Inventor	Papathanassiou et al.
				Group Art. Unit	1631
				Examiner Name	Borin, Michael L.
Sheet 2 of 3				Attorney Docket Number	05213-0294 (43170-252538)
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T*
ms	8	Author: CLEMENTS et al. Title: Kallikreins and kinins in inflammatory-like events in the reproductive tract (Abstract only) Publ: Pharmacological Research Vol/Iss: 35 (6) Pages: 537-540 Date: 06/1997			
	9	Author: DEVARAJ et al. Title: The effects of alpha-tocopherol on critical cells in atherosclerosis Publ: Current Opinion in Lipidology Vol/Iss: 9 (1) Pages: 11-15 Date: 02/1998			
	10	Author: HANADA et al. Title: CARBOXYL TERMINAL BASIC AMINO ACID REGION OF TFPI PREVENTS PROLIFERATION OF HUMAN SMOOTH MUSCLE CELLS BY INHIBITING ACTIVATION OF MAP KINASE KINASE (Abstract only) Publ: Thrombosis and Haemostasis, Supplement Vol/Iss: Pages: Date: 07/2001			
	11	Author: KORFF et al. Title: Integration of Endothelial Cells in Multicellular Spheroids Prevents Apoptosis and Induces Differentiation Publ: The Journal of Cell Biology Vol/Iss: 143 (5) Pages: 1341-1352 Date: 11/30/98			
	12	Author: KORFF et al. Title: Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness Publ: The FASEB Journal Vol/Iss: 15 Pages: 447-457 Date: 02/2001			
	13	Author: KORFF et al. Title: Tensional forces in fibrillar extracellular matrices control directional capillary sprouting Publ: Journal of Cell Science Vol/Iss: 112 (19) Pages: 3249-3258 Date: 10/1999			
ms	14	Author: KUZUYA et al. Title: Antioxidants Stimulate Endothelial Cell Proliferation in Culture Publ: Artery Vol/Iss: 18 (3) Pages: 115-124 Date: 1991			

Unique citation designation number: See attached Kinds of U.S. Patent Documents. Under Office that issued the document. For the WIPO Standard ST-3. For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known		
				Application No.	09/766,778	
				Filing Date	01/22/2001	
				First Named Inventor	Papathanassiou et al.	
				Group Art. Unit	1631	
				Examiner Name	Borin, Michael L.	
Sheet	3	of	3	Attorney Docket Number		05213-0294 (43170-252538)
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T <sup>1</sup>
mm	15	<b>Author:</b> NAKAO-HAYASHI et al. <b>Title:</b> Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells <b>Publ:</b> Atherosclerosis <b>Vol/Iss:</b> 92 <b>Pages:</b> 141-149 <b>Date:</b> 02/1992				
	16	<b>Author:</b> PILGRIM et al. <b>Title:</b> Proliferation kultivierter Endothelzellen unter dem Einfluß von Aprotinin und 4-Aminomethylbezoesaure (no translation) <b>Publ:</b> Biomedica Biochimica Acta <b>Vol/Iss:</b> 45 (8) <b>Pages:</b> 1015-1019 <b>Date:</b> 1986				
	17	<b>Author:</b> RAO et al. <b>Title:</b> Mechanism of Antithrombin III Inhibition of Factor VIIa/Tissue Factor Activity on Cell Surfaces. Comparison With Tissue Factor Pathway Inhibitor/Factor Xa-Induced Inhibition of Factor VIIa/Tissue Factor Activity <b>Publ:</b> Blood <b>Vol/Iss:</b> 85 (1) <b>Pages:</b> 121-129 <b>Date:</b> 01/01/95				
	18	<b>Author:</b> RIDRAY, S. <b>Title:</b> Hyperinsulinemia and smooth muscle cell proliferation <b>Publ:</b> International Journal of Obesity <b>Vol/Iss:</b> 19 Supp.1 <b>Pages:</b> S39-S51 <b>Date:</b> 05/1995				
mm	19	<b>Author:</b> SCHUTTE et al. <b>Title:</b> Additional Aspects of the Effect of Kallikrein on Cell Proliferation <b>Publ:</b> Kinogenases: Kallikrein Symposium Physiol. Prop. Pharmacol. <b>Vol/Iss:</b> 4th Edition <b>Pages:</b> 161-177 <b>Date:</b> 1997 <b>Ration.</b>				

<sup>1</sup> Indicate chain of designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language translation is attached.

RECEIVED

#3

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			Complete if Known		
			Application No.	09/766,778	
			Filing Date	1/22/2001	
			First Named Inventor	Papathanassiu et al.	
			Group Art Unit	1631	
			Examiner Name		
Sheet	1	of	13	Attorney Docket Number	05213-0294 43170-252

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
mm	1	4,552,888	B1	Koppel et al.	11/12/1985	
	2	4,994,443	B1	Folkman et al.	02/19/1991	
	3	5,001,116	B1	Folkman et al.	03/19/1991	
	4	5,021,404	B1	Folkman et al.	06/04/1991	
	5	5,358,959	B1	Halperin et al.	10/25/1994	
mm	6	5,653,744	B1	Khoury et al.	08/05/1997	

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 18, if possible. Applicant to place a check in the box if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known			
				Application No.	09/766,778		
				Filing Date	1/22/2001		
				First Named Inventor	Papathanassiou et al.		
				Group Art Unit	1631		
				Examiner Name			
Sheet	2	of	13	Attorney Docket Number	05213-0294 43170-252538		
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number				
MS	7	WO	97/03560		02/10/1997		No
MS	8	WO	97/09063		03/13/1997		

Indicate the kind of document by the appropriate kind of document symbol in the column for "Kind of Document" by the two-letter code (WIPO Standard ST 3.1). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language translation is attached.

RECEIVED

OCT 18 2001  
TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substantiate for Form 1449/A/PFO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	09/766,778
				Filing Date	1/22/2001
				First Named Inventor	Papathanassiou et al.
				Group Art. Unit	1631
Sheet 3 of 13				Examiner Name	
				Attorney Docket Number	05213-0294 43170-25288
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T
MW	9	<b>Author:</b> ALGIRE, G.H. et al. <b>Title:</b> Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants  <b>Publ:</b> Journal of the National Cancer Institute			
			<b>Vol/Iss:</b> 6	<b>Pages:</b> 73-85	<b>Date:</b> 08/01/45
	10	<b>Author:</b> BREM, H. et al. <b>Title:</b> Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas  <b>Publ:</b> Journal of Neurosurgery			
			<b>Vol/Iss:</b> 74	<b>Pages:</b> 441-446	<b>Date:</b> 03/01/91
	11	<b>Author:</b> CHEN, C. et al. <b>Title:</b> A Strategy to Discover Circulating Angiogenesis Inhibitors Generated by Human Tumors  <b>Publ:</b> Cancer Research			
			<b>Vol/Iss:</b> 55	<b>Pages:</b> 4230-4233	<b>Date:</b> 10/01/95
	12	<b>Author:</b> CAO, Y. et al. <b>Title:</b> gro-B, a-C-X-C- Chemokine is an Angiogenesis Inhibitor that Suppresses the Growth of Lewis Lung Carcinoma in Mice  <b>Publ:</b> Journal of Experimental Medicine			
			<b>Vol/Iss:</b> 182	<b>Pages:</b> 2069-2077	<b>Date:</b> 12/01/95
	13	<b>Author:</b> FOLKMAN, J. <b>Title:</b> Tumor angiogenesis and tissue factor  <b>Publ:</b> Nature Medicine			
			<b>Vol/Iss:</b> 2	<b>Pages:</b> 167-168	<b>Date:</b> 02/01/96
	14	<b>Author:</b> FOLKMAN, J. <b>Title:</b> What is the Evidence that Tumors are Angiogenesis Dependent?  <b>Publ:</b> Journal of the National Cancer Institute			
			<b>Vol/Iss:</b> 82	<b>Pages:</b> 4-6	<b>Date:</b> 01-03-90
MW	15	<b>Author:</b> FOLKMAN, J. <b>Title:</b> Angiogenesis in cancer, vascular, rheumatoid and other disease  <b>Publ:</b> Nature Medicine			
			<b>Vol/Iss:</b> 1(1)	<b>Pages:</b> 27-31	<b>Date:</b> 11/01/95

Unique citation designation number. (See attached kinds of U.S. Patent documents.) Enter Office that issued the document by the two-letter code (WIPO Standard ST 3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language translation is attached.

RECEIVED

OCT 18 2001  
TECH CENTER 1600/2800

Under the Paperwork Reduction Act of 1996, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitution for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	09/766,778
				Filing Date	1/22/2001
				First Named Inventor	Papathanassiou et al.
				Group Art. Unit	1631
Sheet 4 of 13				Examiner Name	
				Attorney Docket Number	05213-0294 43170-2538
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T
MS	16	<b>Author:</b> FOLKMAN, J. <b>Title:</b> Long-term culture of capillary endothelial cells <b>Publ:</b> Proceedings of the National Academy of Science USA <b>Vol/Iss:</b> 76 <b>Pages:</b> 5217-5221 <b>Date:</b> 10/01/79			
	17	<b>Author:</b> FOLKMAN, J. et al. <b>Title:</b> Induction of angiogenesis during the transition from hyperplasia to neoplasia <b>Publ:</b> Nature <b>Vol/Iss:</b> 339 <b>Pages:</b> 58-61 <b>Date:</b> 05/04/89			
	18	<b>Author:</b> FOLKMAN, J. et al. <b>Title:</b> Tumor Behavior in Isolated Perfused Organs in vitro Growth and Metastases of Biopsy Material in Rabbit Thyroid and Canine Intestinal Segment <b>Publ:</b> Annals of Surgery <b>Vol/Iss:</b> 164(3) <b>Pages:</b> 491-501 <b>Date:</b> 09/01/66			
	19	<b>Author:</b> FOLKMAN, J. <b>Title:</b> Angiogenesis and Its Inhibitors <b>Publ:</b> Important Advances in Oncology <b>Vol/Iss:</b> <b>Pages:</b> 42-62 <b>Date:</b> 01/01/85			
	20	<b>Author:</b> FOLKMAN, J. <b>Title:</b> Tumor Angiogenesis: Therapeutic Implications <b>Publ:</b> New England Journal of Medicine <b>Vol/Iss:</b> 18 <b>Pages:</b> 1182-1186 <b>Date:</b> 11/18/71			
	21	<b>Author:</b> GIMBRONE, M. A. <b>Title:</b> Tumor growth and neovascularization: An experimental model using the rabbit cornea et al. <b>Publ:</b> Journal of the National Cancer Institute <b>Vol/Iss:</b> 52(2) <b>Pages:</b> 413-427 <b>Date:</b> 02-01-74			
	22	<b>Author:</b> GIMBRONE, M. A. <b>Title:</b> Tumor dormancy <i>in vivo</i> by Prevention of Neovascularization et al. <b>Publ:</b> Journal of Experimental Medicine <b>Vol/Iss:</b> 136 <b>Pages:</b> 261-276 <b>Date:</b> 01/01/72			

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document by the two-letter code (WIPO Standard ST 3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	09/766,778
				Filing Date	1/22/2001
				First Named Inventor	Papathanassiou et al.
				Group Art. Unit	1631
Examiner Name					
Attorney Docket Number	05213-0294	43750-252338			
Sheet	5	of	13		
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
M	23	<b>Author:</b> GOOD, D.J. et al. <b>Title:</b> A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin <b>Publ:</b> Proceedings of the National Academy of Science USA <b>Vol/Iss:</b> 87 <b>Pages:</b> 6624-6628 <b>Date:</b> 09/01/90			
	24	<b>Author:</b> GROSS, J.L. et al. <b>Title:</b> Modulation of Solid Tumor Growth in vivo by bFGF (Abstract only) <b>Publ:</b> Proceedings of the American Association of Cancer Research <b>Vol/Iss:</b> 31 <b>Pages:</b> 79 <b>Date:</b> 03/01/90			
	25	<b>Author:</b> GUPTA et al. <b>Title:</b> A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4 <b>Publ:</b> Proceedings of the National Academy of Science USA <b>Vol/Iss:</b> 92 <b>Pages:</b> 7799-7803 <b>Date:</b> 08/01/95			
	26	<b>Author:</b> HOLMGREN, L. et al. <b>Title:</b> Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression <b>Publ:</b> Nature Medicine <b>Vol/Iss:</b> 1 (2) <b>Pages:</b> 149-153 <b>Date:</b> 02/01/95			
	27	<b>Author:</b> HOMANDBERG, G.A. et al. <b>Title:</b> Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth <b>Publ:</b> American Journal of Pathology <b>Vol/Iss:</b> 120 <b>Pages:</b> 327-332 <b>Date:</b> 09/01/85			
	28	<b>Author:</b> INGBER, D. et al. <b>Title:</b> Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth <b>Publ:</b> Nature <b>Vol/Iss:</b> 348 <b>Pages:</b> 555-557 <b>Date:</b> 12 06 90			
M	29	<b>Author:</b> KIM, K.J. et al. <b>Title:</b> Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo <b>Publ:</b> Nature <b>Vol/Iss:</b> 362 <b>Pages:</b> 841-844 <b>Date:</b> 04/29/93			

Unique citation designation number. See attached kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	09/766,778
				Filing Date	1/22/2001
				First Named Inventor	Papathanassiou et al.
				Group Art. Unit	1631
Sheet 6 of 13				Examiner Name	
				Attorney Docket Number	05213-0294 43170-0538
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T
mtj	30	<b>Author:</b> KNIGHTON, D. et al. <b>Title:</b> Avascular and Vascular Phases of Tumor Growth in the Chick Embryo <b>Publ:</b> British Journal of Cancer <b>Vol/Iss:</b> 35 <b>Pages:</b> 347-356 <b>Date:</b> 01/01/77			
	31	<b>Author:</b> NGUYEN, M. et al. <b>Title:</b> Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane <b>Publ:</b> Microvascular Research <b>Vol/Iss:</b> 47 <b>Pages:</b> 31-40 <b>Date:</b> 01/01/94			
	32	<b>Author:</b> NGUYEN, M. et al. <b>Title:</b> Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer Patients (Abstract only) <b>Publ:</b> Journal of the National Cancer Institute <b>Vol/Iss:</b> 85(3) <b>Pages:</b> 241-242 <b>Date:</b> 02/03/93			
	33	<b>Author:</b> O'REILLY et al. <b>Title:</b> Endogenous Inhibitors of Angiogenesis (Abstract only) <b>Publ:</b> Proceedings of the American Association of Cancer Research <b>Vol/Iss:</b> 37 <b>Pages:</b> 669 <b>Date:</b> 03/01/96			
	34	<b>Author:</b> O'REILLY et al. <b>Title:</b> Angiostatin induces and sustains dormancy of human primary tumors in mice <b>Publ:</b> Nature Medicine <b>Vol/Iss:</b> 2 (6) <b>Pages:</b> 689-692 <b>Date:</b> 06/01/96			
	35	<b>Author:</b> O'REILLY et al. <b>Title:</b> The Suppression of Tumor Metastases by a Primary Tumor <b>Publ:</b> Surgical Forum <b>Vol/Iss:</b> XLIV <b>Pages:</b> 474-476 <b>Date:</b> 01/01/93			
mm	36	<b>Author:</b> O'REILLY et al. <b>Title:</b> Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma <b>Publ:</b> Cell <b>Vol/Iss:</b> 79 <b>Pages:</b> 315-328 <b>Date:</b> 10/24/94			

Unique citation designation number. See attached kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	09/766,778
				Filing Date	1/22/2001
				First Named Inventor	Papathanassiu et al.
				Group Art. Unit	1631
Sheet 7 of 13				Examiner Name	
				Attorney Docket Number	05213-0294 43170-2538
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T
my	37	<b>Author:</b> O'REILLY et al. <b>Title:</b> Angiostatin: A Circulating Endothelial Cell Inhibitor That Suppresses Angiogenesis and Tumor Growth <b>Publ:</b> Cold Spring Harbor Symposia on Quantitative Biology <b>Vol/Iss:</b> LIX <b>Pages:</b> 471-482 <b>Date:</b> 01/01/94			
	38	<b>Author:</b> OBESO, J. et al. <b>Title:</b> Methods in Laboratory Investigation/A Hemangioendothelioma-Derived Cell Line Its Use as a Model for the Study of Endothelial Cell Biology <b>Publ:</b> Laboratory: Investigation <b>Vol/Iss:</b> 63 (2) <b>Pages:</b> 159 <b>Date:</b> 01/01/90			
	39	<b>Author:</b> PARANGI, S. et al. <b>Title:</b> Antiangiogenic therapy of transgenic mice impairs de novo tumor growth <b>Publ:</b> Proceedings of the National Academy of Science USA <b>Vol/Iss:</b> 93 <b>Pages:</b> 2002-2007 <b>Date:</b> 03/01/96			
	40	<b>Author:</b> PASSANITI, A. et al. <b>Title:</b> Methods in Laboratory Investigation/A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor <b>Publ:</b> Laboratory: Investigation <b>Vol/Iss:</b> 67(4) <b>Pages:</b> 519-528 <b>Date:</b> 01/01/92			
	41	<b>Author:</b> RASTINEJAD, F. et al. <b>Title:</b> Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene <b>Publ:</b> Cell <b>Vol/Iss:</b> 56 <b>Pages:</b> 345-355 <b>Date:</b> 02/10/89			
	42	<b>Author:</b> MAIONE, T. E. et al. <b>Title:</b> Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides <b>Publ:</b> Science <b>Vol/Iss:</b> 247 <b>Pages:</b> 77-79 <b>Date:</b> 01/05/90			
mm	43	<b>Author:</b> SRIVASTAVA, A. et al. <b>Title:</b> The Prognostic Significance of Tumorvascularity in Intermediate-Thickness (0.76-4.0 mm Thick) Skin Melanoma <b>Publ:</b> American Journal of Pathology <b>Vol/Iss:</b> 133 (2) <b>Pages:</b> 419-424 <b>Date:</b> 11/01/88			

Unique citation designation number. See attached kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	09/766,778
				Filing Date	1/22/2001
				First Named Inventor	Papathanassiou et al.
				Group Art. Unit	1631
Sheet 8 of 13				Examiner Name	
				Attorney Docket Number	05213-0294 43170-292538
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T
mm	44	<b>Author:</b> TEICHER, B.A. et al. <b>Title:</b> Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents <b>Publ:</b> International Journal of Cancer <b>Vol/Iss:</b> 57 (6) <b>Pages:</b> 920-925 <b>Date:</b> 01/01/94			
	45	<b>Author:</b> VOEST, E.E. et al. <b>Title:</b> Inhibition of Angiogenesis in Vivo by Interleukin 12 <b>Publ:</b> Journal of the National Cancer Institute <b>Vol/Iss:</b> 87 <b>Pages:</b> 581-586 <b>Date:</b> 04/19/95			
	46	<b>Author:</b> WEIDNER, N. et al. <b>Title:</b> Tumor angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma <b>Publ:</b> Journal of the National Cancer Institute <b>Vol/Iss:</b> 84 <b>Pages:</b> 1875-1887 <b>Date:</b> 12/16/92			
	47	<b>Author:</b> WEIDNER, N. et al. <b>Title:</b> Tumor Angiogenesis Correlates with Metastasis in Invasive Prostate Carcinoma <b>Publ:</b> American Journal of Pathology <b>Vol/Iss:</b> 143 (2) <b>Pages:</b> 401-409 <b>Date:</b> 08/01/93			
	48	<b>Author:</b> WEIDNER, N. et al. <b>Title:</b> Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma <b>Publ:</b> New England Journal of Medicine <b>Vol/Iss:</b> 324 (1) <b>Pages:</b> 1-8 <b>Date:</b> 01/03/91			
	49	<b>Author:</b> CRUM, R. et al. <b>Title:</b> A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment <b>Publ:</b> SCIENCE <b>Vol/Iss:</b> 230 <b>Pages:</b> 1375-1378 <b>Date:</b> 12/20/85			
mm	50	<b>Author:</b> BROZE, G.J., Jr. et al. <b>Title:</b> Tissue Factor Pathway Inhibitor and the Revised Theory of Coagulation <b>Publ:</b> Annu. Rev. Med. <b>Vol/Iss:</b> 46 <b>Pages:</b> 103-112 <b>Date:</b> 1995			

Unique citation designation number. See attached kinds of U.S. Patent Documents. Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	09/766,778
				Filing Date	1/22/2001
				First Named Inventor	Papathanassiou et al.
				Group Art. Unit	1631
Sheet 9 of 13				Examiner Name	
				Attorney Docket Number	05213-0294 43170-25238
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T
ms	51	<b>Author:</b> BOK, R.A. et al. <b>Title:</b> Quantitative Characterization of the Binding of Plasminogen to Intact Fibrin Clots, Lysine-Sepharose, and Fibrin Cleaved by Plasmin <b>Publ:</b> Biochemistry <b>Vol/Iss:</b> 24 <b>Pages:</b> 3279-3286 <b>Date:</b> 1985			
	52	<b>Author:</b> BROZE et al. <b>Title:</b> <b>Publ:</b> Biochemistry <b>Vol/Iss:</b> 29 (33) <b>Pages:</b> 7539-7546 <b>Date:</b> 1990			
	53	<b>Author:</b> CAO, Y. et al. <b>Title:</b> Kringle Domains of Human Angiostatin <b>Publ:</b> The Journal of Biological Chemistry <b>Vol/Iss:</b> 271 <b>Pages:</b> 1-7 <b>Date:</b> 11/15/96			
	54	<b>Author:</b> CARDIFF, R.D. <b>Title:</b> Protoneoplasia: The Molecular Biology of Murine Mammary Hyperplasia (Abstract only) <b>Publ:</b> Advances in Cancer Research <b>Vol/Iss:</b> 42 <b>Pages:</b> 167-190 <b>Date:</b> 01/01/84			
	55	<b>Author:</b> CONTRINO, J. <b>Title:</b> <i>In situ</i> detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease <b>Publ:</b> Nature Medicine <b>Vol/Iss:</b> 2 (2) <b>Pages:</b> 209-215 <b>Date:</b> 02/01/96			
	56	<b>Author:</b> DAVIES et al. <b>Title:</b> Pathobiology of Intimal Hyperplasia (Abstract only) <b>Publ:</b> British Journal of Surgery <b>Vol/Iss:</b> 81 <b>Pages:</b> 1254-1269 <b>Date:</b> 01/01/94			
ms	57	<b>Author:</b> DINBERGS et al. <b>Title:</b> <b>Publ:</b> Journal of Biological Chemistry <b>Vol/Iss:</b> 271 (47) <b>Pages:</b> 22822-22829 <b>Date:</b> 12/01/96			

Unique citation designation number. See attached kinds of U.S. Patent Documents. Enter Office that issued the document by the two-letter code (WIPO Standard ST 3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language translation is attached.

 RECEIVED  
 OCT 18 2001  
 TECH CENTER 1600/2902

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	09/766,778
				Filing Date	1/22/2001
				First Named Inventor	Papathanassiou et al.
				Group Art. Unit	1631
Sheet 10 of 13				Examiner Name	
				Attorney Docket Number	05213-0294 43170-252538
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T
mm	58	<b>Author:</b> ENJOYUJI, K. et al. <b>Title:</b> Effect of Heparin on the Inhibition of Factor Xa by Tissue Factor Pathway Inhibitor: A Segment, Gly - Phe, of the third Kunitz Domain is a Heparin-Binding Site <b>Publ:</b> Biochemistry			<b>Vol/Iss:</b> 34 (17) <b>Pages:</b> 5725-5735 <b>Date:</b> 01/01/95
	59	<b>Author:</b> FERENCZY, A. et al. <b>Title:</b> The cytodynamics of endometrial hyperplasia and carcinoma <b>Publ:</b> Annales de Pathologie			<b>Vol/Iss:</b> 3 (3) <b>Pages:</b> 189-201 <b>Date:</b> 01/01/83
	60	<b>Author:</b> HAAS, A.F. et al. <b>Title:</b> Angiolymphoid Hyperplasia with Eosinophilia of the Hand (Abstract only) <b>Publ:</b> Journal of Dermatologic Surgery and Oncology			<b>Vol/Iss:</b> 17 <b>Pages:</b> 731-734 <b>Date:</b> 01/01/91
	61	<b>Author:</b> ISHINO et al. <b>Title:</b> <b>Publ:</b> Folia Psychiat. Neurol. Jap.			<b>Vol/Iss:</b> 27 (3) <b>Pages:</b> 207-221 <b>Date:</b> 01/01/73
	62	<b>Author:</b> KAMIKUBO, Y. et al. <b>Title:</b> Human Recombinant Tissue-Factor Pathway Inhibitor Prevents the Proliferation of Cultured Human Neonatal Aortic Smooth Muscle Cells <b>Publ:</b> FEBS Letters			<b>Vol/Iss:</b> 407 <b>Pages:</b> 116-120 <b>Date:</b> 01/01/97
	63	<b>Author:</b> KEHREL, B. <b>Title:</b> <b>Publ:</b> Semin. Throm. Hemost.			<b>Vol/Iss:</b> 21 (2) <b>Pages:</b> 123-129 <b>Date:</b> 01/01/95
mm	64	<b>Author:</b> KHOURI, R.K. et al. <b>Title:</b> Local Application of Tissue Factor Pathway Inhibitor (TFPI) Inhibits Intimal Hyperplasia Induced by Arterial Interventions <b>Publ:</b> Surgical Forum			<b>Vol/Iss:</b> 46 <b>Pages:</b> 389-391 <b>Date:</b> 1995

Unique citation designator number. (See attached kinds of U.S. Patent documents.) Enter Office that issued the document by the two-letter code (WIPO Standard ST 3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	09/766,778
				Filing Date	1/22/2001
				First Named Inventor	Papathanassiou et al.
				Group Art. Unit	1631
Examiner Name					
Sheet	11	of	13	Attorney Docket Number	05213-0294 43170-232538
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T
mly	65	<b>Author:</b> KOYAMA et al. <b>Title:</b> <b>Publ:</b> American Journal of Pathology			<b>Vol/Iss:</b> 148 (3) <b>Pages:</b> 749-761 <b>Date:</b> 01/01/96
	66	<b>Author:</b> LINDAHL, A. <b>Title:</b> Coagulation Inhibition and Activation in Pancreatic Cancer <b>Publ:</b> Cancer			<b>Vol/Iss:</b> 70 (8) <b>Pages:</b> 2067-2072 <b>Date:</b>
	67	<b>Author:</b> LUPU, C. et al. <b>Title:</b> Thrombin Induces the Redistribution and Acute Release of Tissue Factor Pathway Inhibitor from Specific Granules within Human Endothelial Cells in Culture <b>Publ:</b> Arteriosclerosis, Thrombosis, and Vascular Biology			<b>Vol/Iss:</b> 15 (11) <b>Pages:</b> 2055-2062 <b>Date:</b> 11/01/95
	68	<b>Author:</b> MCGEE, J. et al. <b>Title:</b> Simultaneous Expression of Tissue Factor and Tissue Factor Pathway Inhibitor by Human Monocytes. A Potential Mechanism for Localized Control of Blood Coagulation <b>Publ:</b> Journal of Experimental Medicine			<b>Vol/Iss:</b> 179 <b>Pages:</b> 1847-1854 <b>Date:</b> 06/01/94
	69	<b>Author:</b> MIYAGI, Y. et al. <b>Title:</b> cDNA Cloning and mRNA Expression of a Serine Protease Inhibitor Secreted by Cancer Cells: Identification as Placental Protein 5 and Tissue Factor Pathway Inhibitor-2 <b>Publ:</b> Journal of Biochemistry			<b>Vol/Iss:</b> 116 <b>Pages:</b> 939-942 <b>Date:</b> 01/01/94
	70	<b>Author:</b> MOSS, G.W. et al. <b>Title:</b> <b>Publ:</b> Journal of Gen. Physiology			<b>Vol/Iss:</b> 108 (6) <b>Pages:</b> 473-484 <b>Date:</b> 12/01/96
mly	71	<b>Author:</b> NARITA, M. et al. <b>Title:</b> Two Receptor Systems are Involved in the Plasma Clearance of Tissue Factor Pathway Inhibitor in vivo <b>Publ:</b> Journal of Biological Chemistry			<b>Vol/Iss:</b> 270 (42) <b>Pages:</b> 24800-24804 <b>Date:</b> 01/01/95

Unique citation designation number. (See attached kinds of U.S. Patent Documents). Enter Office that issued the document by the two-letter code (WIPO Standard ST 3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Substitution for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	09/766,778
				Filing Date	1/22/2001
				First Named Inventor	Papathanassiou et al.
				Group Art Unit	1631
Sheet 12 of 13				Examiner Name	
				Attorney Docket Number	05213-0294 43170-252538

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
MW	72	<b>Author:</b> NIWANO et al. <b>Title:</b> <b>Publ:</b> Journal of Laboratory Clinical Medicine <b>Vol/Iss:</b> 125 (2) <b>Pages:</b> 215-256 <b>Date:</b> 01/01/95	
	73	<b>Author:</b> NOVOTNY, W.F. et al. <b>Title:</b> Purification and Characterization of the Lipoprotein-Associated Coagulation Inhibitor from Human Plasma <b>Publ:</b> Journal of Biological Chemistry <b>Vol/Iss:</b> 264 <b>Pages:</b> 18832-18837 <b>Date:</b> 01/01/89	
	74	<b>Author:</b> OSTERUD, B. et al. <b>Title:</b> Sites of Tissue Factor Pathway Inhibitor (TFPI) and Tissue Factor Expression under Physiologic and Pathologic Conditions <b>Publ:</b> Thrombosis and Haemostasis <b>Vol/Iss:</b> 73 <b>Pages:</b> 873-875 <b>Date:</b> 01/01/95	
	75	<b>Author:</b> PETERSON, L.C. et al. <b>Title:</b> Inhibitory Properties of a Novel Human Kunitz-Type Protease Inhibitor Homologous to Tissue Factor Pathway Inhibitor <b>Publ:</b> Biochemistry <b>Vol/Iss:</b> 35 <b>Pages:</b> 266-272 <b>Date:</b> 01/01/96	
	76	<b>Author:</b> SAMANMA, M.M. et al. <b>Title:</b> Mechanisms for the Antithrombotic Activity in Man of Low Molecular Weight Heparins (LMWHs) <b>Publ:</b> Haemostasis <b>Vol/Iss:</b> 24 <b>Pages:</b> 105-117 <b>Date:</b> 01/01/94	
	77	<b>Author:</b> STEINHUBL, S.R. et al. <b>Title:</b> Local Delivery of Tissue Factor Pathway Inhibitor (TFPI) to Reduce Neointimal Proliferation in the Porcine Coronary Balloon Injury Model (Abstract only) <b>Publ:</b> Journal of the American College of Cardiology <b>Vol/Iss:</b> 29 (2) <b>Pages:</b> 975-7 <b>Date:</b> 02/01/97 Supp. A	
MW	78	<b>Author:</b> SRIGLEY, J.R. <b>Title:</b> <b>Publ:</b> Seminars in Diagnostic Pathology <b>Vol/Iss:</b> 5 (3) <b>Pages:</b> 254-720 <b>Date:</b> 08/01/88	

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	09/766,778
				Filing Date	1/22/2001
				First Named Inventor	Papathanassiou et al.
				Group Art. Unit	1631
				Examiner Name	
Sheet	13	of	13	Attorney Docket Number	05213-0294 43170-252538
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
MM	79	<b>Author:</b> TAYLOR, S. et al. <b>Title:</b> Protamine is an inhibitor of angiogenesis <b>Publ:</b> <u>Nature</u> <b>Vol/Iss:</b> 297 <b>Pages:</b> 307-312 <b>Date:</b> 05/01/82			
	80	<b>Author:</b> WARSHAWSKY, I. <b>Title:</b> The Carboxy Terminus of Tissue Factor Pathway Inhibitor is Required for Interacting with Hepatoma Cells in Vitro and In Vivo <b>Publ:</b> <u>The American Society for Clinical Investigation</u> <b>Vol/Iss:</b> 95 <b>Pages:</b> 1773-1782 <b>Date:</b> 01/01/95			
	81	<b>Author:</b> WARSHAWSKY, I. <b>Title:</b> The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor <b>Publ:</b> <u>Proceedings of the National Academy of Science USA</u> <b>Vol/Iss:</b> 91 <b>Pages:</b> 6664-6668 <b>Date:</b> 01/01/94			
MM	82	<b>Author:</b> SPRECHER, C.A. <b>Title:</b> Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor <b>Publ:</b> <u>Proceedings of the National Academy of Science USA</u> <b>Vol/Iss:</b> 91 <b>Pages:</b> 3353-3357 <b>Date:</b> 01/01/94			

Unique citation designation number. See attached kinds of U.S. Patent documents. Enter office that issued the document by the two-letter code (WIPO Standard ST 3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language translation is attached.